[vc_row][vc_column width=”1/1″][vc_column_text]


[/vc_column_text][dt_gap height=”25″][vc_column_text]April 2014: IntelliSyn successfully reaches its milestone with Epigenetix and partners its BRD4 inhibitor project with the NeoMed Institute to advance to clinical trials.

July 2013: IntelliSyn expands to new facilities at the NeoMed Institute the Montreal Technopark. It is a first-tier R&D facility that has been specifically designed for early R&D work.

April 2013: IntelliSyn receives NSERC grant in collaboration with Prof. N. Moitessier of McGill University to advance “Novel molecular scaffolds as epigenetic-directed anti-cancer drug candidates”.

January 2013: IntelliSyn is named as a member of Pharmaqam; a consortium of 50 researchers from 17 different institutions with common interests in biopharmaceutical research. The center focuses on the molecular aspects of biopharmaceutical research and brings together complementary, cutting-edge research essential for efficient drug discovery.

August 2012: IntelliSyn is selected as the exclusive Med Chem partner for Epigenetix, a US-based biotechnology group focusing on novel epigenetic mechanisms for cancer and other indications. IntelliSyn provides full medicinal chemistry design, synthesis, and DMPK support.

June 2012: IntelliSyn is founded at the Biotech Incubator at the University of Quebec in downtown Montreal.[/vc_column_text][/vc_column][/vc_row]